HCM
APLS

Highbridge Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Highbridge Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-59,664
Closed -$1.44M – 64
2019
Q3 		$1.44M Buy
+59,664
New +$1.64M 0.21% 45

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Highbridge Capital Management's APLS Position: Q4 2019 in Review

Highbridge Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2019, closing a stake of 59,664 shares — an estimated $1.44M sold.

Highbridge Capital Management first reported a position in APLS in Q3 2019 and held it in 1 quarter. The position peaked at $1.44M in Q3 2019. 133 funds tracked by Wall St. Rank hold APLS as of Q4 2019.

  • Highbridge Capital Management reported no remaining Apellis Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Highbridge Capital Management sold 59,664 Apellis Pharmaceuticals shares in Q4 2019, an estimated $1.44M.
  • Highbridge Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Highbridge Capital Management's Apellis Pharmaceuticals position peaked at $1.44M in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2019.

Based on Highbridge Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.